A Multicentre Trial with Bacampicillin (Penglobe®) in the Treatment of Respiratory Tract Infections in General Practice

1986 ◽  
Vol 14 (2) ◽  
pp. 110-114
Author(s):  
R Pauwels ◽  
J J Detiège
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Clinical Outcome ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Multicentre Trial ◽  
Good For ◽  
Tract Infections

Nine hundred and eleven patients were admitted to a multicentre trial with bacampicillin (Penglobe®) in respiratory tract infections. Of these it was possible to evaluate 830 with respect to efficacy and side-effects. In most cases a dosage of 400 mg × 2 was used but in severe cases 800 mg × 2 was used. The clinical outcome was assessed as good for 79% of the patients, while 17% showed an improvement and 3% a failure. The tolerance was good with an over-all incidence of 8% side-effects, of which dyspepsia was the most common.

Broad Spectrum Oral Amoxycillin* in Acute Respiratory Tract Infections

1984 ◽  
Vol 12 (3) ◽  
pp. 207-209
Author(s):  
S Kalachand
Keyword(s):  
Side Effects ◽  
Tract Infection ◽  
Clinical Outcome ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Acute Respiratory Tract Infection ◽  
Treatment Side Effects ◽  
Tract Infections

The clinical outcome of 143 patients presenting with acute respiratory tract infection and treated with oral amoxycillin is described. A clinical success rate of 92% was observed after 1 week's therapy with only one patient deteriorating whilst on treatment. Side-effects were mild and limited to 7% of patients.

A Multicentre General Practice Study Comparing Pivampicillin (Pondocillin) and Amoxycillin (Amoxil) in Respiratory Tract Infections

1983 ◽  
Vol 11 (6) ◽  
pp. 370-374 ◽  
Author(s):  
D G Moran
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Respiratory Tract ◽  
Otitis Media ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Acute Bronchitis ◽  
Lower Respiratory Tract Infections ◽  
Practice Study ◽  
Tract Infections

Seven-day courses of either pivampicillin (Pondocillin) 500 mg twice daily or amoxycillin (Amoxil) 250 mg three times daily were compared in a multicentre general practice study in 463 patients with symptoms of upper or lower respiratory tract infections. Patients were stratified into four diagnostic groups: sinusitis, otitis media, throat infections, and acute bronchitis, and randomly allocated to treatment within these groups. There was an over-all response of 93% in the 227 patients receiving 12-hourly pivampicillin compared with 90% for the 236 patients receiving 8-hourly amoxycillin. Patients suffering from acute bronchitis responded significantly better to pivampicillin (Pondocillin) than to amoxycillin. Side-effects were reported by 15·6% of patients in the amoxycillin group and 14·0% in the pivampicillin group.

Treatment Pattern of Acute Respiratory Tract Infections in General Practice with 3rd generation Oral Cefixime in Bangladesh

1970 ◽  
Vol 40 (1) ◽  
pp. 39-42
Author(s):  
SZ Hossain ◽  
RF Khan ◽  
UK Barua ◽  
MJ Sobhan
Keyword(s):  
General Practice ◽  
Clinical Outcome ◽  
Adverse Events ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Signs And Symptoms ◽  
Treatment Pattern ◽  
Major Health Problem ◽  
Physician Visits ◽  
Tract Infections

Respiratory tract infections (RTIs) are a major health problem in developing countries. RTIs are the most common reason for physician visits and prescription of antibiotics. Cefixime is quickly establishing as a potent broad-spectrum antibiotic with a variety of indications. This observational study was designed to describe the treatment pattern of third generation oral cefixime in managing RTIs in general practice. This noncontrolled, multicenter, observational registry was carried out from March 2009 to July 2010. During this period 2400 patients aged 3 years to 76 years suffering from RTIs were enrolled by general physicians throughout the country. Study variable were socio demographic, signs and symptoms, clinical diagnosis, investigations, antimicrobial prescribed and clinical outcome. Clinical outcome was determined based on improvement of signs and symptoms. Compliance, efficacy and tolerance were assessed on days 7 and 10. The enrolled patients were considered for analysis. The mean age was 26.59 (± 18.10) years and 62% of patients were male. Common presenting signs and symptoms were fever, cough, shortness of breath and increased sputum volume in 80%, 75%, 39%, and 12% respectively. From prescriptions, pneumonia, acute bronchitis, acute exacerbation of chronic bronchitis and lung abscess were the diagnosis in 42%, 26%, 24% and 3% of the prescriptions, respectively. Following the treatment with cefixime clinically cured, much improved and better were obtained in 77%, 21% and 2% respectively. Furthermore, the rate of adverse events were insignificant. The study showed clinical symptoms improved rapidly and high rates of clinical cure were achieved. More over, the rate of adverse events were relatively quite low. The results supports the use of cefixime for a variety of respiratory infections in adult and pediatric patients in Bangladesh. DOI: http://dx.doi.org/10.3329/bmj.v40i1.9962 BMJ 2011; 40(1): 39-42

scholarly journals Determinants of antibiotic overprescribing in respiratory tract infections in general practice

2005 ◽  
Vol 56 (5) ◽  
pp. 930-936 ◽  
Author(s):  
Annemiek E. Akkerman ◽  
Marijke M. Kuyvenhoven ◽  
Johannes C. van der Wouden ◽  
Theo J. M. Verheij
Keyword(s):  
General Practice ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Tract Infections
Sign in / Sign up

Export Citation Format

Share Document